157 related articles for article (PubMed ID: 311678)
21. [Cancer and immunity].
Cerottini JC; Mach JP
Rev Med Suisse Romande; 1974 Sep; 94(9):675-84. PubMed ID: 4438877
[No Abstract] [Full Text] [Related]
22. Manipulation of immunologically reactive cell populations in vitro. Outline of an approach to specific immunotherapy of cancer.
Bach ML; Bach FH; Zoschke DC
Isr J Med Sci; 1973 Mar; 9(3):344-9. PubMed ID: 4145460
[No Abstract] [Full Text] [Related]
23. Tumor immunology. A neurosurgical perspective. I. General concepts of tumor immunology.
Apuzzo ML; Sheikh KM
Bull Los Angeles Neurol Soc; 1976 Oct; 41(4):168-75. PubMed ID: 1088581
[TBL] [Abstract][Full Text] [Related]
24. [Cancer immunotherapy: immunologic bases, reality and hopes].
Dietrich PY; Farace F; Caignard A; Escudier B; Triebel F
Bull Cancer; 1993 Jul; 80(7):584-600. PubMed ID: 8204939
[TBL] [Abstract][Full Text] [Related]
25. [A scientist's day-dream or future reality? Specific immunotherapy against cancer].
Kiessling R; Kärre K
Lakartidningen; 1997 Apr; 94(17):1595-600. PubMed ID: 9182159
[No Abstract] [Full Text] [Related]
26. Prospects for the immunotherapy of cancer. Part II: current status of immunotherapy.
Pilch YH; Myers GH; Sparks FC; Golub SH
Curr Probl Surg; 1975 Feb; ():1-61. PubMed ID: 1092529
[No Abstract] [Full Text] [Related]
27. Progress in human tumour immunology and immunotherapy.
Rosenberg SA
Nature; 2001 May; 411(6835):380-4. PubMed ID: 11357146
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy in cancer treatment. A comparative study with chronic muco-cutaneous candidiasis.
Higgs JM
Clin Oncol; 1980 Jun; 6(2):95-112. PubMed ID: 6967793
[No Abstract] [Full Text] [Related]
29. The immunology of cancer: avenues to immunotherapy.
Woods AH
Ariz Med; 1973 Jul; 30(7):463-83. PubMed ID: 4581414
[No Abstract] [Full Text] [Related]
30. [Cellular immunotherapy as combination partners for the immune checkpoint blockade].
Rössig C
Oncol Res Treat; 2014; 37 Suppl 4():14-5. PubMed ID: 25301192
[No Abstract] [Full Text] [Related]
31. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.
Boon T; Coulie P; Marchand M; Weynants P; Wölfel T; Brichard V
Important Adv Oncol; 1994; ():53-69. PubMed ID: 8206495
[No Abstract] [Full Text] [Related]
32. T-cell epitope peptide vaccines.
Elsawa SF; Rodeberg DA; Celis E
Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
[TBL] [Abstract][Full Text] [Related]
33. Monitoring cellular immune responses to cancer immunotherapy.
Morse MA; Clay TM; Hobeika AC; Mosca PJ; Lyerly HK
Curr Opin Mol Ther; 2001 Feb; 3(1):45-52. PubMed ID: 11249731
[TBL] [Abstract][Full Text] [Related]
34. Analyses and perspectives in cancer immunotherapy.
Nguyen van Binh P; Duc HT
Biomed Pharmacother; 2006 Nov; 60(9):621-8. PubMed ID: 16978826
[TBL] [Abstract][Full Text] [Related]
35. Introduction: diagnosis and immunotherapy of cancer.
Klein E
Natl Cancer Inst Monogr; 1972 Dec; 35():331-9. PubMed ID: 4349151
[No Abstract] [Full Text] [Related]
36. [Recent progress of cancer immunology and its problems].
Hashimoto Y
Tanpakushitsu Kakusan Koso; 1992 Jan; 37(1):10-7. PubMed ID: 1542731
[No Abstract] [Full Text] [Related]
37. Clinical aspects of cancer immunity.
Moore GE
Prog Clin Cancer; 1973; 5():107-20. PubMed ID: 4571116
[No Abstract] [Full Text] [Related]
38. Immunology in tumor therapeutics: an overview.
Barber HR
Del Med J; 1980 Apr; 52(4):197-209. PubMed ID: 6153996
[No Abstract] [Full Text] [Related]
39. Universal and stemness-related tumor antigens: potential use in cancer immunotherapy.
Parmiani G; Russo V; Marrari A; Cutolo G; Casati C; Pilla L; Maccalli C; Rivoltini L; Castelli C
Clin Cancer Res; 2007 Oct; 13(19):5675-9. PubMed ID: 17908956
[No Abstract] [Full Text] [Related]
40. Cancer vaccines: reborn or just recycled?
Berd D
Semin Oncol; 1998 Dec; 25(6):605-10. PubMed ID: 9865675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
